Mirabegron

Base Information Edit

Chemical Name:Mirabegron
CAS No.:223673-61-8
Deprecated CAS:928324-05-4
Molecular Formula:C21H24N4O2S
Molecular Weight:396.513
Hs Code.:
European Community (EC) Number:800-126-3
UNII:MVR3JL3B2V
DSSTox Substance ID:DTXSID101021648
Nikkaji Number:J1.648.518G
Wikipedia:Mirabegron
Wikidata:Q3702534
NCI Thesaurus Code:C90633
RXCUI:1300786
Pharos Ligand ID:FQU48133K3VG
Metabolomics Workbench ID:63801
ChEMBL ID:CHEMBL2095212
Mol file:223673-61-8.mol

Synonyms:2-(2-aminothiazol-4-yl)-4'-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)acetanilide;Betanis;Betmiga;mirabegron;YM 178;YM-178

Suppliers and Price of Mirabegron

Supply Marketing:Edit

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

TRC
Mirabegron
10g
$ 655.00

TRC
Mirabegron
1g
$ 145.00

TRC
Mirabegron
25mg
$ 85.00

Tocris
Mirabegron ≥98%(HPLC)
5
$ 79.00

DC Chemicals
Mirabegron >98%
100 mg
$ 150.00

DC Chemicals
Mirabegron >98%
250 mg
$ 300.00

Crysdot
Mirabegron 98+%
10mg
$ 336.00

Crysdot
Mirabegron 98+%
50mg
$ 839.00

ChemScene
Mirabegron 99.79%
100mg
$ 650.00

ChemScene
Mirabegron 99.79%
5mg
$ 80.00

Total 180 raw suppliers

Chemical Property of Mirabegron Edit

Chemical Property:

Appearance/Colour:Light yellow to yellow solid
Vapor Pressure:5.45E-20mmHg at 25°C
Melting Point:138-140 °C
Refractive Index:1.68
Boiling Point:690.008 °C at 760 mmHg
PKA:13.51±0.70(Predicted)
Flash Point:371.104 °C
PSA：128.51000
Density:1.314 g/cm³
LogP:3.81730
Storage Temp.:-20°C Freezer
Solubility.:Chloroform (Slightly, Heated), Methanol (Slightly)
XLogP3:2.1
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:9
Exact Mass:396.16199719
Heavy Atom Count:28
Complexity:467

Purity/Quality:

99% ^*data from raw suppliers

Mirabegron ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Drug Classes:Urologic Agents
Canonical SMILES:C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
Isomeric SMILES:C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
Recent ClinicalTrials:Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Recent EU Clinical Trials:β3 adrenergic agoniSt treatment in chronic Pulmonary HypERtEnsion secondary to heart failure: a randomized placebo-controlled phase 2 clinical trial
Recent NIPH Clinical Trials:The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder
Description Betanis (Mirabegron) was approved in July 2011 by the Japanese Ministry of Health, Labour, and Welfare for the treatment of urgency, urinary frequency, and urinary urge urinary incontinence associated with overactive bladder (OAB). Mirabegron is synthesized by coupling 4-nitrophenethyl amine to (R)-2-hydroxy-2-phenylacetic acid. The resulting amide is reduced to an amine. The nitro group is then reduced and the resulting aniline is coupled to 2-(2-aminothiazol-4-yl) acetic acid to give mirabegron. Mirabegron has an EC50 of 22 nM (intrinsic activity=0.8) for β3-AR with no detectable activity for β1- andβ2-AR (EC50>10,000 nM). In an anesthetized rat rhythmic bladder contraction model in which bladder contractions are induced by saline, mirabegron at 3 mg/kg iv decreased the frequency of rhythmic bladder contraction without suppressing contraction amplitude. These data suggest that the activation of β3-AR increases bladder capacity without influencing the frequency of bladder contraction.
Uses Mirabegron is a selective β3-adrenoceptor agonist with EC50 of 22.4 nM. A potent bladder relaxant compound Potent bladder relaxant and reagent for diabetes remedy.;Labeled Mirabegron, intended for use as an internal standard for the quantification of Mirabegron by GC- or LC-mass spectrometry.
Clinical Use Mirabegron is an orally active β3-adrenoceptor agonist currently in development by Astellas Pharma for the treatment of overactive bladder (OAB). The drug is a nanomolar EC50 antagonist against human β3-AR biochemical assays with good selectivity over b1- and β2-ARs. Mirabegron demonstrates a novel mechanism by targeting the β3-AR for bladder relaxation to help manage OAB symptoms such as increased urinary urgency and frequency and urgency incontinence. However, mirabegron is a cytochrome P450 2D6 inhibitor, and it raises a concern for drug–drug interaction with concomitant administration of other cytochrome P450 2D6 substrates.
Drug interactions Potentially hazardous interactions with other drugs None known

Technology Process of Mirabegron

There total 44 articles about Mirabegron which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 100.0%

: 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide acetate salt

: 223673-61-8,1796931-48-0
(R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide

Guidance literature:: With water; In water; at 80 ℃; for 24h; Reagent/catalyst; Temperature;

Reference yield: 93.5%

: 29676-71-9
2-amino-4-thiazoleacetic acid

: 391901-45-4
YM-208876

: 223673-61-8,1796931-48-0
(R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide

Guidance literature:: YM-208876; With hydrogenchloride; In water; for 0.25h;

2-amino-4-thiazoleacetic acid; With hydrogenchloride; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In water; at 20 ℃; for 1h; pH=5 - 6;